The Effect of Adjuvant IMOD therapy on the Immunological Status of HIV-positive Patients: A Double-Blind Randomized Controlled Trial

How to cite

Baees, Mehdi Gholamzadeh. 2015. "The Effect of Adjuvant IMOD therapy on the Immunological Status of HIV-positive Patients: A Double-Blind Randomized Controlled Trial." AEA RCT Registry. AEARCTR-0000745. https://doi.org/10.1257/rct.745-1.0

Download: BibTeX · RIS — for reference managers without a browser translator. Zotero and most others pick up this page's citation metadata directly.

Mehdi Gholamzadeh Baees*

* Primary investigator

Registry ID
AEARCTR-0000745
DOI
https://doi.org/10.1257/rct.745-1.0
First registered
Last updated
Status
Completed
Trial dates
2013-12-05 – 2014-07-23
Countries
Iran (Islamic Republic of) (Qom)
Registry record
http://www.socialscienceregistry.org/trials/745

Abstract

Introduction: HIV infection is a major threat to global health. So far, it has claimed the lives of 25 million people in the world. Recently, Iranian scientists have produced a drug called IMOD to strengthen the immune system. The present study examines the effect of addition of IMOD to the HAART regimen on the immunological status of HIV-positive patients referred to the Counseling Center for Behavioral Diseases in Qom in 2013.
Methods: In a parallel Double-Blind Randomized Controlled Trial 60 HIV-positive patients with indications for treatment with HAART regimen were enrolled. The participants were randomly assigned, following simple randomization procedures (1 : 1), to receive IMOD or placebo along with the common treatments Participants and those assessing the outcomes were blinded to group assignment. Patient assigned to placebo received the same solution as IMOD but without IMOD Active ingredients control group those received HAART therapy and the intervention group (the patients underwent IMOD infusion in addition to HAART therapy). The IMOD used in this study was a vial containing 120 mg in 4 ml. Random sampling was performed. CBC, LFT,BUN, Cr, TLC, CD4 were measured before and after treatment. The collected data were analyzed using SPSS 16.
Results: The mean age of patients in the intervention and control groups was 35.5 ± 5.97 and 34 ± 6.72 years, respectively. The CD4 changes in women received IMOD was significant (P <0.05). A significant correlation was found between CD4 changes and age in the intervention group (P <0.05). A significant correlation was found between the mean CD4 counts before and after treatment in the intervention group (P = 0.041). A significant difference was also found between the CD4 counts before and after treatment in the intervention group (P = 0.003). There was no significant difference between the mean TLC before and after treatment in the intervention group (P = 0.938).
Conclusion: According to the results, IMOD can be included in the drug regimen of HIV-positive patients or those with AIDS to enhance the immunological status.
Keywords: IMOD, HAART, HIV +, AIDS, CD4

Intervention

In a parallel Double-Blind Randomized Controlled Trial 60 HIV-positive patients with indications for treatment with HAART regimen were enrolled. The participants were randomly assigned, following simple randomization procedures (1 : 1), to receive IMOD or placebo along with the common treatments Participants and those assessing the outcomes were blinded to group assignment. Patient assigned to placebo received the same solution as IMOD but without IMOD Active ingredients control group those received HAART therapy and the intervention group (the patients underwent IMOD infusion in addition to HAART therapy). The IMOD used in this study was a vial containing 120 mg in 4 ml. Random sampling was performed. CBC, LFT,BUN, Cr, TLC, CD4 were measured before and after treatment. The collected data were analyzed using SPSS 16.

Experimental design

In a parallel Double-Blind Randomized Controlled Trial 60 HIV-positive patients with indications for treatment with HAART regimen were enrolled. The participants were randomly assigned, following simple randomization procedures (1 : 1), to receive IMOD or placebo along with the common treatments Participants and those assessing the outcomes were blinded to group assignment. Patient assigned to placebo received the same solution as IMOD but without IMOD Active ingredients control group those received HAART therapy and the intervention group (the patients underwent IMOD infusion in addition to HAART therapy).

Design details

Randomization method
Block randomization, Generalized by Excel
Randomization unit
No clustered or more than one level randomization
Clusters
60
Observations
60
Arms
30 patient in intervention group and 30 patient in control group
Primary outcomes
The mean age of patients in the intervention and control groups was 35.5 ± 5.97 and 34 ± 6.72 years, respectively. The CD4 changes in women received IMOD was significant (P <0.05). A significant correlation was found between CD4 changes and age in the intervention group (P <0.05). A significant correlation was found between the mean CD4 counts before and after treatment in the intervention group (P = 0.041). A significant difference was also found between the CD4 counts before and after treatment in the intervention group (P = 0.003). There was no significant difference between the mean TLC before and after treatment in the intervention group (P = 0.938).

Cited by

No citation data available for this registration yet.

Keywords